A completed phase II study in which patients with melanoma stages II or IV were treated with a dendritic cell-based mRNA vaccination encoding several tumor antigens—including MAGE-A3, plus ipilimumab, which is a monoclonal antibody (mAb) directed against CTL4—yielded encouraging results. The gene discussed is MAGEA3; the disease is melanoma.